✦ LIBER ✦

PCN16 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR HER-2 POSITIVE EARLY BREAST CANCER IN TAIWAN

✍ Scribed by TY Chao; SC Chen; KJ Chang; HK Chang; DR Chen; MF Hou; RK Hsieh; WT Huang; LM Tseng; HC Wang; L Yang; A Cirrincione

Book ID: 119596035
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 71 KB
Volume: 10
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)65174-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN7 COST-EFFECTIVENESS ANALYSIS OF ADJU

PCN7 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2-POSITIVE EARLY BREAST CANCER IN POLISH SETTING

✍ E Orlewska; T Pienkowski; K Drosik; M Gyldmark; R Aultman; M Szkultecka-Debek 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

PCN81 A Cost-Effectiveness Analysis of A

PCN81 A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/NEU-Positive Breast Cancer in Colombia

✍ Buendia rodriguez, J.A.; Vallejos, C. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PCN61 COST-EFFECTIVENESS OF 1-YEAR ADJUV

PCN61 COST-EFFECTIVENESS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY FOR EARLY STAGE OF HER2-POSITIVE BREAST CANCER

✍ T.T.T. Nguyen; R. Yagudina; A.U. Kulikov 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PCN20 COST-EFFECTIVENESS ANALYSIS OF ADJ

PCN20 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE SAUDI ARABIAN SETTING

✍ H AlOmar; AS Zazaa; M AlFayyadh; JA Ray 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB

Cost-effectiveness analysis of trastuzum

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

✍ Louis P. Garrison Jr; Deborah Lubeck; Deepa Lalla; Virginia Paton; Amylou Dueck; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

## Abstract ## BACKGROUND. Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. A cost‐effectiveness analysis was performed to assess clinical and economic implications of adding t

PCN4 BUDGET IMPACT ANALYSIS OF ADJUVANT

PCN4 BUDGET IMPACT ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2-POSITIVE EARLY BREAST CANCER IN POLISH SETTING

✍ E Orlewska; R Aultman; M Krzakowski; T Pienkowski; K Drosik; M Szkultecka-Debek 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB